EDGAR·FLOW

IMPACT BIOMEDICAL INC. — Form 8-K

Filed November 18, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 28/100
What the filing says
Impact BioMedical amended its merger agreement with Zoar Limited twice (June 30 and August 13, 2026). Key changes: Company Share Consideration reduced from 168.1M to 168.0M shares (93.38% to 93.32% of post-closing shares); DSS Inc. receives additional 100,000 shares in third batch (total 228,000 shares to DSS; CEO Heuszel receives 22,000); merger termination deadline extended from July 1 to November 20, 2026. No dollar valuation disclosed; deal structure and consideration remain substantially unchanged.
Why this rating

Routine amendments to M&A timeline and share issuances; minimal economic change relative to $7.6M company; deal already in progress, no new major terms.

View original filing on SEC.gov ↗ IBO · stock on Yahoo Finance ↗

See more from November 18, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.